Dr. Jeffrey Clarke, MD
NPI: 1295909034
Total Payments
$144,902
2024 Payments
$36,980
Companies
14
Transactions
112
Medicare Patients
830
Medicare Billing
$124,184
Payment Breakdown by Category
Consulting$85,656 (59.1%)
Other$30,725 (21.2%)
Research$16,008 (11.0%)
Travel$10,162 (7.0%)
Food & Beverage$2,328 (1.6%)
Education$24.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $85,656 | 28 | 59.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $28,925 | 8 | 20.0% |
| Unspecified | $16,008 | 10 | 11.0% |
| Travel and Lodging | $10,162 | 23 | 7.0% |
| Food and Beverage | $2,328 | 40 | 1.6% |
| Honoraria | $1,800 | 1 | 1.2% |
| Education | $24.00 | 2 | 0.0% |
Payments by Type
General
$128,895
102 transactions
Research
$16,008
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $43,384 | 28 | $0 (2023) |
| Merck Sharp & Dohme LLC | $37,892 | 35 | $0 (2023) |
| Amgen Inc. | $28,039 | 13 | $0 (2024) |
| PFIZER INC. | $13,210 | 11 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $6,776 | 14 | $0 (2024) |
| Daiichi Sankyo Inc. | $3,768 | 2 | $0 (2024) |
| G1 Therapeutics, Inc. | $3,125 | 1 | $0 (2021) |
| Genentech USA, Inc. | $2,880 | 2 | $0 (2021) |
| ABBVIE INC. | $2,175 | 1 | $0 (2024) |
| Coherus Biosciences Inc. | $1,800 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $36,980 | 29 | Amgen Inc. ($17,662) |
| 2023 | $25,528 | 11 | AstraZeneca Pharmaceuticals LP ($12,589) |
| 2022 | $6,603 | 5 | Amgen Inc. ($3,894) |
| 2021 | $17,733 | 7 | AstraZeneca Pharmaceuticals LP ($12,620) |
| 2020 | $9,923 | 7 | PFIZER INC. ($5,186) |
| 2019 | $16,288 | 18 | Merck Sharp & Dohme Corporation ($10,571) |
| 2018 | $31,636 | 33 | Merck Sharp & Dohme Corporation ($25,065) |
| 2017 | $210.43 | 2 | Merck Sharp & Dohme Corporation ($120.83) |
All Payment Transactions
112 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | PFIZER INC. | BRAFTOVI (Drug), VIZIMPRO, LORBRENA | — | In-kind items and services | $3,200.00 | Research |
| Study: BRAFTOVI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/14/2024 | Amgen Inc. | IMDELLTRA (AMG 757) (Biological), LUMAKRAS | Consulting Fee | Cash or cash equivalent | $8,840.00 | General |
| Category: Hematology | ||||||
| 11/27/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $2,397.50 | General |
| 11/19/2024 | Amgen Inc. | LUMAKRAS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,630.00 | General |
| Category: Oncology | ||||||
| 11/12/2024 | ABBVIE INC. | — | — | Cash or cash equivalent | $2,175.00 | Research |
| Study: SMALL CELL LUNG CANCER (SCLC) VIRTUAL PANEL DISCUSSION | ||||||
| 11/06/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| 10/14/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $40.63 | General |
| 10/14/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $19.25 | General |
| 10/09/2024 | Amgen Inc. | LUMAKRAS (Drug) | Food and Beverage | In-kind items and services | $48.34 | General |
| Category: Oncology | ||||||
| 09/14/2024 | PFIZER INC. | XALKORI (Drug), MEKTOVI | — | In-kind items and services | $940.00 | Research |
| Study: XALKORI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/07/2024 | Amgen Inc. | IMDELLTRA (AMG757) (Biological) | — | In-kind items and services | $24.15 | Research |
| Study: Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage Small Cell Lung Cancer: DeLLphi-305 Phase 3 Trial • Category: Hematology | ||||||
| 08/07/2024 | PFIZER INC. | — | — | In-kind items and services | $330.00 | Research |
| Study: DACOMITINIB CLINICAL PUBLICATION PROGRAM | ||||||
| 06/20/2024 | Amgen Inc. | LUMAKRAS (Drug) | — | In-kind items and services | $2,059.43 | Research |
| Study: AMG 510 Ph1b Master Protocol 20190135 • Category: Oncology | ||||||
| 05/03/2024 | Coherus Biosciences Inc. | — | Honoraria | Cash or cash equivalent | $1,800.00 | General |
| 05/03/2024 | PFIZER INC. | LORBRENA (Drug), XALKORI, MEKTOVI | — | In-kind items and services | $330.00 | Research |
| Study: LORLATINIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 03/26/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 03/18/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,010.00 | General |
| 03/08/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $30.00 | General |
| 03/01/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $64.99 | General |
| 03/01/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $49.99 | General |
| 03/01/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $27.44 | General |
| 02/08/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,680.00 | General |
| 02/01/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $423.49 | General |
| 02/01/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $64.99 | General |
| 02/01/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $64.99 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| BRAFTOVI CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| ENCORAFENIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4) | G1 Therapeutics, Inc. | $3,125 | 1 |
| SMALL CELL LUNG CANCER (SCLC) VIRTUAL PANEL DISCUSSION | ABBVIE INC. | $2,175 | 1 |
| AMG 510 Ph1b Master Protocol 20190135 | Amgen Inc. | $2,059 | 1 |
| XALKORI CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| AMG 510 - Adv. KRAS G12C solid tumors_20190135 | Amgen Inc. | $623.93 | 1 |
| DACOMITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| LORLATINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage Small Cell Lung Cancer: DeLLphi-305 Phase 3 Trial | Amgen Inc. | $24.15 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 225 | 335 | $110,513 | $33,104 |
| 2022 | 5 | 186 | 293 | $102,794 | $30,441 |
| 2021 | 4 | 177 | 308 | $104,330 | $31,501 |
| 2020 | 7 | 242 | 371 | $111,682 | $29,137 |
Total Patients
830
Total Services
1,307
Medicare Billing
$124,184
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 73 | 132 | $45,408 | $13,199 | 29.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 54 | 54 | $26,460 | $7,358 | 27.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 31 | 72 | $18,000 | $6,512 | 36.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 16 | 16 | $7,776 | $2,110 | 27.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 23 | 27 | $6,885 | $1,878 | 27.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 17 | 17 | $3,026 | $1,026 | 33.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 17 | $2,958 | $1,022 | 34.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 69 | 130 | $44,866 | $13,776 | 30.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 53 | 53 | $25,970 | $6,895 | 26.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 14 | 50 | $12,500 | $4,093 | 32.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 17 | 18 | $8,748 | $2,895 | 33.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 33 | 42 | $10,710 | $2,781 | 26.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 69 | 155 | $53,320 | $17,228 | 32.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 52 | 52 | $25,480 | $7,379 | 29.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 42 | 56 | $14,280 | $3,907 | 27.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 14 | 45 | $11,250 | $2,988 | 26.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 76 | 129 | $44,376 | $10,642 | 24.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 19 | 64 | $16,000 | $5,331 | 33.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 40 | 40 | $19,600 | $5,169 | 26.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 52 | 76 | $19,380 | $4,433 | 22.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 12 | $5,832 | $1,947 | 33.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 30 | 32 | $5,504 | $1,251 | 22.7% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2020 | 13 | 18 | $990.00 | $363.71 | 36.7% |
About Dr. Jeffrey Clarke, MD
Dr. Jeffrey Clarke, MD is a Student in an Organized Health Care Education/Training Program healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/14/2008. The National Provider Identifier (NPI) number assigned to this provider is 1295909034.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Clarke, MD has received a total of $144,902 in payments from pharmaceutical and medical device companies, with $36,980 received in 2024. These payments were reported across 112 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($85,656).
As a Medicare-enrolled provider, Clarke has provided services to 830 Medicare beneficiaries, totaling 1,307 services with total Medicare billing of $124,184. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Location Durham, NC
- Active Since 04/14/2008
- Last Updated 06/27/2008
- Taxonomy Code 390200000X
- Entity Type Individual
- NPI Number 1295909034
Products in Payments
- KEYTRUDA (Biological) $29,261
- TAGRISSO (Drug) $23,909
- LUMAKRAS (Drug) $14,556
- IMFINZI (Biological) $11,849
- IMDELLTRA (AMG 757) (Biological) $8,840
- IMFINZI (Drug) $7,626
- BRAFTOVI (Drug) $6,400
- XALKORI (Drug) $5,300
- Cosela (Drug) $3,125
- Alecensa (Biological) $2,880
- RYBREVANT (Drug) $1,689
- LORBRENA (Drug) $354.00
- CYRAMZA (Drug) $89.60
- IMDELLTRA (AMG757) (Biological) $24.15
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Durham
Mr. Marat Fudim, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $580,115
Student in an Organized Health Care Education/Training Program $580,115
Dr. Joseph Mammarappallil, Phd, Md, PHD, MD
Student in an Organized Health Care Education/Training Program — Payments: $480,745
Student in an Organized Health Care Education/Training Program $480,745
Brandon Howard, Phd, PHD
Student in an Organized Health Care Education/Training Program — Payments: $307,589
Student in an Organized Health Care Education/Training Program $307,589
William Bullock, M.d., Ph.d, M.D., PH.D
Student in an Organized Health Care Education/Training Program — Payments: $132,715
Student in an Organized Health Care Education/Training Program $132,715
Dr. Neel Thomas, M.d,, M.p.h, M.D,, M.P.H
Student in an Organized Health Care Education/Training Program — Payments: $122,974
Student in an Organized Health Care Education/Training Program $122,974
Cristiana Chase, D.o, D.O
Student in an Organized Health Care Education/Training Program — Payments: $103,128
Student in an Organized Health Care Education/Training Program $103,128